Background Image

OUR APPROACH TO ANALGESIA

Analgesia

Over the past 60 years, Mundipharma has introduced a number of products that have transformed the way pain is treated, offering oral, transdermal and parenteral delivery of analgesia to suit patient needs.

Product name Product description
OxyContin® Oxycodone Hydrochloride, extended-release tablets
OxyNorm® Oxycodone Hydrochloride, immediate-release
TarginActTM Oxycodone Hydrochloride and Naloxone Hydrochloride, prolonged-release
BuTrans® Buprenorphine transdermal patch
MST Continus® Prolonged Release Morphine Sulphate
MSITM Morphine Sulphate Injection
Tramundin® Tramadol Hydrochloride Tablets

The product range includes:

OxyNorm® ® formulations– capsules, liquid, concentrate immediate-release formulations that contain the active ingredient oxycodone. Indicated for the treatment of moderate to severe pain in patients with cancer and post-operative pain. For the treatment of severe pain requiring the use of a strong opioid.

OxyNorm® Injection is indicated for the treatment of moderate to severe pain in patients with cancer and post-operative pain. For the treatment of severe pain requiring the use of a strong opioid.

TarginActTM tablets, a prolonged-release oral combination of the opioid agonist oxycodone and the opioid antagonist naloxone, is a recent addition to the oxycodone range. Indicated for severe pain, which can be adequately managed only with opioid analgesics.

The opioid antagonist naloxone is added to counteract opioid-induced constipation by blocking the action of oxycodone at opioid receptors locally in the gut.

MST® Continus® film-coated tablets contain morphine sulfate. Indicated for the prolonged relief of severe pain.

MSITM solution for injection contains morphine sulfate. Indicated for severe and most severe pain.

BuTrans® is a transdermal patch that delivers a constant dose of buprenorphine during seven days of wear. Indicated for the treatment of non-malignant pain of moderate intensity when an opioid is necessary for obtaining adequate pain.

Tramundin® prolonged release tablets have the active ingredient tramadol. Indicated for the management of moderate to severe analgesia.

® OxyContin, OxyNorm, BuTrans, MST Continus, Tramundin are registered trademarks of Mundipharma AG in UAE and are either registered trademarks or trademarks in other countries.

™ TarginAct & MSI are trademarks of Mundipharma AG in UAE and are either registered trademarks or trademarks in other countries.

Please refer to individual countries for full local prescribing information and indications as approved by relative health authorities

* Not all products or indications are available in all countries. Products are currently under registrations across Middle East, Turkey and Africa Region and subject to approval according to local laws and regulations.

Please refer to your local representative office and the locally approved prescribing information for more details on the product and indications. Furthermore, Mundipharma Middle East FZLLC provides the information for r eaders from many countries in the ME region as of this date and does not undertake any obligation to update any forward-looking statements contained in this newsletter as a result of new information, future events or otherwise.

↓
WordPress Video Lightbox Plugin